Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

Acta Neuropathologica

Volumn 108, Issue 1, 2004, Pages 49-56

  Okamoto, Yoshikazu ^a   Di Patre, Pier Luigi ^a   Burkhard, Christoph ^a   Horstmann, Sonja ^a   Jourde, Benjamin ^a   Fahey, Michael ^a   Schüler, Danielle ^b   Probst Hensch, Nicole M ^b   Yasargil, M Gazi ^c   Yonekawa, Yasuhiro ^d   Lütolf, Urs M ^d   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Cancer Registry   (Switzerland)

^c Division of Health Services Research   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Incidence rate; Low grade diffuse astrocytoma; Oligoastrocytoma; Oligodendroglioma; Population based study; Survival

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; FEMALE; GENE MUTATION; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SWITZERLAND; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

AGE FACTORS; AGED; ASTROCYTOMA; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEUROSURGICAL PROCEDURES; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242722352     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-004-0861-z     Document Type: Article

References (38)

1. Central Brain Tumor Registry of the United States (CBTRUS; http://www.cbtrus.org) 2002
2. AI Sarraj S, Bridges LR (1995) p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9: 143-149
3. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 4:825-830
4. Buckner JC, Gesme D, Jr., O'Fallon JR, Hammack JE, Staffod S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255
5. Burkhard C, Patre PL di, Schüler D, Ysargil MG, Lütolf U, Kleihues P, Ohgaki H (2003) A population-based study on the incidence and survival of patients with pilocytic astrocytoma. J Neurosurg 98:1170-1174
6. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
7. Chozick BS, Pezzullo JC, Epstein MH, Finch PW (1994) Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831-837
8. Henderson KH, Shaw EG (2001) Randomized trials of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol 11:145-151
9. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR (1998) Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724-729
10. Iuzzolino P, Ghimenton C, Nicolato A, Giorgiutti F, Fina P, Doglioni C, Barbareschi M (1994) p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer 69: 586-591
11. Kleihues P, Cavenee WK (eds) (2000) World Health Organization Classification of Tumours: pathology and genetics of tumours of the nervous system. IARC Press, Lyon
12. Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal MM, Cavenee WK (2000) Diffuse astrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 22-26
13. Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, Schlegel U (1994) TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10:143-149
14. Krouwer HG, Davis RL, Silver P, Prados M (1991) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:399-406
15. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, Deimling A von (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098-1104
16. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C - A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715-1719
17. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539-543
18. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253-1262
19. Ohgaki H, Vital A, Kleihues P, Hainaut P (2000) Li-Fraumeni syndrome and TP53 germline mutations. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 231-234
20. Ohshima H, Bartsch H (1994) Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 305:253-264
21. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117-1124
22. Pignatti F, van den BM, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084
23. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330
24. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligoastrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 65-67
25. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligodendroglioma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 56-61
26. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111-126
27. Reis RM, Hara A, Kleihues P, Ohgaki H (2001) Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 102:422-425
28. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61:58-63
29. Schlegel U (1994) p53: an important or most overvalued tumor gene? Laryngol Rhinol Otol 73:651-653
30. Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-oncol 5:153-160
31. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645
32. Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M (2000) A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 247:297-302
33. van der Bent MJ, Kros JM, Heimans JJ, Pronk LC, Van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51:1140-1145
34. Wallner KE, Gonzales M, Sheline GE (1988) Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 68:684-688
35. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H (1998) p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 95:559-564
36. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-224
37. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76:277-284
38. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2001) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267-275